Low-Dose MAGL Inhibitor Maintained Pain Relief and Stomach Protection Without Causing Tolerance
Repeated low-dose administration of a MAGL inhibitor retained its pain-relieving and stomach-protecting effects without causing CB1 receptor tolerance or cannabinoid dependence, unlike high doses which caused both.
Quick Facts
What This Study Found
The MAGL inhibitor JZL184 blocks the enzyme that breaks down the endocannabinoid 2-AG, boosting natural cannabinoid signaling. When given at high doses (16+ mg/kg daily for 6 days), it caused CB1 receptor downregulation, desensitization, antinociceptive tolerance, cross-tolerance to THC, and cannabinoid dependence.
However, at low doses (8 mg/kg or less), JZL184 maintained its pain-relieving effects in a neuropathic pain model and stomach-protective effects against NSAID damage, with no CB1 receptor downregulation, no tolerance, no cross-tolerance to THC, and no dependence. This demonstrates that partial MAGL inhibition can provide therapeutic benefits without the drawbacks of full inhibition.
Key Numbers
High dose (16+ mg/kg): CB1 downregulation, desensitization, tolerance, cross-tolerance to THC, dependence. Low dose (8 mg/kg or less): no downregulation, no desensitization, maintained pain relief, maintained gastroprotection, no THC cross-tolerance, no dependence.
How They Did This
Mouse studies using repeated daily JZL184 at multiple doses. CB1 receptor density measured by [3H]SR141716A binding. CB1 function measured by CP55,940-stimulated GTPgammaS binding. Behavioral assessments: neuropathic pain (chronic constriction injury), gastroprotection (NSAID-induced hemorrhage), THC cross-tolerance, rimonabant-precipitated withdrawal.
Why This Research Matters
This study solved a key problem in endocannabinoid drug development. Full MAGL inhibition produces tolerance just like chronic THC, but partial inhibition maintains the benefits. This provides a roadmap for developing MAGL inhibitors as medicines: keep the dose low enough for partial inhibition.
The Bigger Picture
This study established a crucial therapeutic principle: the dose that produces tolerance is higher than the dose needed for therapeutic effects. By staying below the tolerance threshold, MAGL inhibitors could provide sustained pain and inflammation relief through the body's own endocannabinoid system without the problems of chronic THC use.
What This Study Doesn't Tell Us
Mouse studies may not translate to humans. Only one MAGL inhibitor was tested. The neuropathic pain model and gastroprotection model are specific paradigms. The 6-day treatment period is relatively short. Whether partial MAGL inhibition maintains efficacy over months or years is unknown.
Questions This Raises
- ?Where is the dose threshold between therapeutic effect and tolerance in humans?
- ?Would low-dose MAGL inhibitors be effective for chronic pain conditions?
- ?Could MAGL inhibitors replace NSAIDs for patients at risk of stomach ulcers?
Trust & Context
- Key Stat:
- Low doses maintained therapeutic effects while high doses caused tolerance and dependence
- Evidence Grade:
- Comprehensive preclinical study with multiple converging measures; moderate evidence for a therapeutic window.
- Study Age:
- Published in 2013. MAGL inhibitor drug development has continued based on this partial-inhibition principle.
- Original Title:
- Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 345(3), 492-501 (2013)
- Authors:
- Kinsey, Steven G(12), Wise, Laura E(3), Ramesh, Divya(6), Abdullah, Rehab, Selley, Dana E, Cravatt, Benjamin F, Lichtman, Aron H
- Database ID:
- RTHC-00691
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is MAGL and why does inhibiting it matter?
MAGL is the enzyme that breaks down 2-AG, one of the brain's main endocannabinoids. Blocking MAGL raises 2-AG levels, enhancing natural cannabinoid signaling. This is different from adding an external cannabinoid like THC because it boosts the body's own system. The key finding here is that partial blockade (low-dose inhibitor) provides benefits without the tolerance and dependence seen with full blockade.
Could this lead to better pain medications?
Potentially. The study showed that low-dose MAGL inhibition relieved neuropathic pain and protected against stomach damage (a major side effect of common painkillers like ibuprofen) without causing tolerance. If this translates to humans, MAGL inhibitors could offer a new class of pain medication that works through the endocannabinoid system without the drawbacks of either THC or NSAIDs.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- cannabis-and-arthritis-research
Cite This Study
https://rethinkthc.com/research/RTHC-00691APA
Kinsey, Steven G; Wise, Laura E; Ramesh, Divya; Abdullah, Rehab; Selley, Dana E; Cravatt, Benjamin F; Lichtman, Aron H. (2013). Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.. The Journal of pharmacology and experimental therapeutics, 345(3), 492-501. https://doi.org/10.1124/jpet.112.201426
MLA
Kinsey, Steven G, et al. "Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.." The Journal of pharmacology and experimental therapeutics, 2013. https://doi.org/10.1124/jpet.112.201426
RethinkTHC
RethinkTHC Research Database. "Repeated low-dose administration of the monoacylglycerol lip..." RTHC-00691. Retrieved from https://rethinkthc.com/research/kinsey-2013-repeated-lowdose-administration-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.